XML 66 R35.htm IDEA: XBRL DOCUMENT
v3.25.3

SHARE-BASED COMPENSATION (Tables) | 12 Months Ended
--- | ---
Jul. 31, 2025
Defined Benefit Plan Disclosure [Line Items] |
SUMMARY OF NUMBER OF OPTIONS GRANTED | SUMMARY OF NUMBER OF OPTIONS GRANTED
|  | Number of options |  |  | Weighted average exercise price (*) |  |  | Weighted average remaining contractual term (in years) |  |  | Aggregate intrinsic value |
Balance as of July 31, 2023 and 2024 |  |  | 14,183 |  |  | $ | 923.53 |  |  |  | 2.52 |  |  | $ | - |
Granted (i) |  |  | 333 |  |  |  | 60.00 |  |  |  | 4.45 |  |  |  | - |
Forfeited |  |  | (1,265 | ) |  |  | 978.16 |  |  |  |  |  |  |  |  |
Balance as of July 31, 2025 |  |  | 13,251 |  |  |  | 896.61 |  |  |  | 1.62 |  |  |  | - |
Exercisable as of July 31, 2024 |  |  | 13,152 |  |  | $ | 924.60 |  |  |  | 2.41 |  |  | $ | - |
Exercisable as of July 31, 2025 |  |  | 13,251 |  |  | $ | 896.61 |  |  |  | 1.62 |  |  | $ | - |
| (i) | On January 16, 2025, the Company granted 333 stock options to a consultant at an exercise price of $60.00 per share. All options vested in full on April 16, 2025. The options expire on January 16, 2030. The grant-date fair value of the award was $16,242.
| (ii) | The weighted-average grant date per-share fair value of stock options granted during 2025 and 2024 was $48.77 and $ nil respectively. As of July 31, 2025, there are $nil of total unrecognized costs related to share-based compensation, as all costs have been fully recognized.
| (*) | certain options are exercisable in Canadian dollars and translated to US Dollars at year end.
SCHEDULE OF FAIR VALUE MEASUREMENT OF EQUITY - SETTLED SHARE OPTIONS | SCHEDULE OF FAIR VALUE MEASUREMENT OF EQUITY - SETTLED SHARE OPTIONS
|  | Year ended July 31, |
|  | 2025 |  |  | 2024(*) |
Dividend yield |  |  | 0.00 | % |  |  | n/a |
Expected volatility of the share prices |  |  | 112 | % |  |  | n/a |
Risk-free interest rate |  |  | 4.45 | % |  |  | n/a |
Expected term (in years) |  |  | 5.0 |  |  |  | n/a |
(*) | There were no options grants during the year end July 31, 2024.
SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS | SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS
Exercise price |  |  | Options outstanding as of July 31, 2025 |  |  | Weighted average remaining contractual term (years) |  |  | Options exercisable as of July 31, 2025 |  |  | Weighted average remaining contractual term (years) |  |  | Expiry Date
$ | 60.00 |  |  |  | 333 |  |  |  | 4.45 |  |  |  | 333 |  |  |  | 4.45 |  |  | January 16, 2030
$ | 904.50 |  |  |  | 2,663 |  |  |  | 2.89 |  |  |  | 2,663 |  |  |  | 2.89 |  |  | June 20, 2028
$ | 1,074.00 |  |  |  | 136 |  |  |  | 2.58 |  |  |  | 136 |  |  |  | 2.58 |  |  | February 27, 2028
$ | 907.97 |  |  |  | 1,195 |  |  |  | 2.01 |  |  |  | 1,195 |  |  |  | 2.01 |  |  | August 02, 2027
$ | 706.50 |  |  |  | 206 |  |  |  | 1.81 |  |  |  | 206 |  |  |  | 1.81 |  |  | May 20, 2027
$ | 1,126.50 |  |  |  | 1,000 |  |  |  | 1.54 |  |  |  | 1,000 |  |  |  | 1.54 |  |  | February 16, 2027
$ | 1,270.50 |  |  |  | 3,160 |  |  |  | 1.45 |  |  |  | 3,160 |  |  |  | 1.45 |  |  | January 13, 2027
$ | 1,074.83 |  |  |  | 81 |  |  |  | 1.25 |  |  |  | 81 |  |  |  | 1.25 |  |  | November 01, 2026
$ | 636.00 |  |  |  | 400 |  |  |  | 0.72 |  |  |  | 400 |  |  |  | 0.72 |  |  | April 19, 2026
$ | 636.00 |  |  |  | 4,077 |  |  |  | 0.66 |  |  |  | 4,077 |  |  |  | 0.66 |  |  | March 29, 2026
|  |  |  |  | 13,251 |  |  |  |  |  |  |  | 13,251 |  |  |  |  |  |  |
SCHEDULE OF RESTRICTED STOCK UNITS GRANTED | The following table summarizes the number of RSU’s granted to directors under the Omnibus Plan for year ended July 31, 2025: SCHEDULE OF RESTRICTED STOCK UNITS GRANTED
|  | Number of |  |  |  |
|  | RSU’s |  |  | Aggregate |
|  | outstanding |  |  | intrinsic value |
Balance, July 31, 2024 |  |  | 128 |  |  | $ | 14,400 |
Granted (i) |  |  | 6,166 |  |  |  | 370,000 |
Exercised(ii) |  |  | (6,294 | ) |  |  | (384,000 | )
Balance, July 31, 2025 |  |  | - |  |  | $ | - |
| (i) | On January 16, 2025, the Company granted 5,833 RSU’s to the Chief Executive Officer (“CEO”) as compensation for deferred salary, with immediate vesting. The fair value of these RSUs was $350,000, offsetting previously accrued compensation owed to the CEO. Additionally, on the same date, the Company granted 333 RSUs to a consultant, which fully vested on April 16, 2025. The fair value of these RSUs was $20,000.
| (ii) | All RSUs outstanding were exercised on July 13, 2025. As a result, no RSUs remained outstanding as of July 31, 2025.
SCHEDULE OF SHARE-BASED COMPENSATION EXPENSES | f. The total share-based compensation expense related to all of the Company’s equity-based awards, recognized for the years ended July 31, 2025 and 2024 is comprised as follows: SCHEDULE OF SHARE-BASED COMPENSATION EXPENSES
|  | Year ended July 31, |
|  | 2025 |  |  | 2024 |
Research and development expenses |  | $ | 120,050 |  |  | $ | 734,986 |
General and administrative expenses |  |  | 656,829 |  |  |  | 1,069,092 |
Total share-based compensation |  | $ | 776,879 |  |  | $ | 1,804,078 |
Bria Pro Therapeutics Corp [Member] |
Defined Benefit Plan Disclosure [Line Items] |
SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS | SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS
Exercise Price |  |  | Options outstanding as of July 31, 2025 |  |  | Options exercisable as of July 31, 2025 |  |  | Expiry Date
$ | 0.0933 |  |  |  | 440,000 |  |  |  | 440,000 |  |  | June 20, 2028
$ | 0.1108 |  |  |  | 21,000 |  |  |  | 21,000 |  |  | February 27, 2028
$ | 0.0984 |  |  |  | 180,100 |  |  |  | 180,100 |  |  | August 02, 2027
$ | 0.0729 |  |  |  | 31,000 |  |  |  | 31,000 |  |  | May 20, 2027
$ | 0.1162 |  |  |  | 150,000 |  |  |  | 150,000 |  |  | February 16, 2027
$ | 0.1310 |  |  |  | 524,700 |  |  |  | 524,700 |  |  | January 13, 2027
$ | 0.1165 |  |  |  | 12,600 |  |  |  | 12,600 |  |  | November 01, 2026
$ | 0.0888 |  |  |  | 100,000 |  |  |  | 100,000 |  |  | September 01, 2026
$ | 0.0656 |  |  |  | 60,000 |  |  |  | 60,000 |  |  | April 19, 2026
$ | 0.0656 |  |  |  | 612,000 |  |  |  | 612,000 |  |  | March 29, 2026
|  |  |  |  | 2,131,400 |  |  |  | 2,131,400 |  |  |

X
- Definition Schedule Of Share Based Compensation Expenses [TableTextBlock] + References No definition available. + Details
Name: | BCTX_ScheduleOfShareBasedCompensationExpensesTableTextBlock
Namespace Prefix: | BCTX_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (k) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (j)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (j)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (j)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (j)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (c)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (c)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-7 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (q) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (m) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5 + Details
Name: | us-gaap_DefinedBenefitPlanDisclosureLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=BCTX_BriaProTherapeuticsCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |